Implantable Cardiac Devices Market Report 2026

Implantable Cardiac Devices Market Overview

• Implantable Cardiac Devices market size has reached to $13.34 billion in 2025 • Expected to grow to $20.33 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: Rising Incidence Of Heart Diseases Fuels Growth In The Implantable Cardiac Devices Market • Market Trend: Technological Innovations in Implantable Cardiac Devices • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Implantable Cardiac Devices Market?

Implantable cardiac devices are medical devices surgically placed inside the body to help manage heart conditions, particularly those related to abnormal heart rhythms (arrhythmias) or heart failure. These devices monitor the heart's activity and, in many cases, deliver electrical impulses to regulate or correct abnormal heartbeats. The main types of implantable cardiac devices include pacemakers, implantable cardioverter defibrillators (ICD), and biventricular implantable cardioverter defibrillators (BI-V ICD). A pacemaker is a small medical device implanted under the skin of the chest to help regulate irregular heartbeats by using electrical impulses to prompt the heart to beat at a normal rate when the heart's natural pacemaker fails, playing a crucial role in treating bradycardia and other arrhythmias. The applications include bradycardia, tachycardia, heart failure, and others for end users such as hospitals, specialty clinics, and others.

What Is The Implantable Cardiac Devices Market Growth Forecast?

The implantable cardiac devices market size is expected to see strong growth in the next few years. It will grow to $20.33 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing demand for remote patient monitoring, rising focus on minimally invasive cardiac treatments, expansion of digital healthcare integration, growing innovation in battery and lead technologies, increasing use of ai-assisted cardiac diagnostics. Major trends in the forecast period include increasing adoption of miniaturized implantable devices, rising integration of remote cardiac monitoring, growing use of mri-compatible implants, expansion of cardiac resynchronization therapies, enhanced focus on device longevity and reliability.

Global Implantable Cardiac Devices Market Segmentation

1) By Type: Pacemaker, Implantable Cardioverter Defibrillator (ICD), Biventricular Implantable Cardioverter Defibrillator (BI-V ICD) 2) By Application: Bradycardia, Tachycardia, Heart Failure, Other Applications 3) By End User: Hospitals, Specialty Clinics, Other End Users Subsegments: 1) By Pacemaker: Single-Chamber Pacemakers, Dual-Chamber Pacemakers, Rate-Responsive Pacemakers 2) By Implantable Cardioverter Defibrillator (ICD): Transvenous ICDs, Subcutaneous ICDs 3) By Biventricular Implantable Cardioverter Defibrillator (BI-V ICD): Standard BI-V ICDs, Advanced BI-V ICDs with Cardiac Resynchronization Therapy (CRT)

What Is The Driver Of The Implantable Cardiac Devices Market?

The rising incidence of heart diseases is expected to propel the growth of the implantable cardiac devices market. The rise in heart diseases can be attributed to the increasing prevalence of risk factors such as poor diet, sedentary lifestyle, obesity, and chronic conditions like diabetes and hypertension. Additionally, aging populations and rising stress levels further contribute to the higher incidence of cardiovascular conditions. Implantable cardiac devices are used to manage and treat conditions such as heart failure, arrhythmias, and coronary artery disease. This increased need accelerates innovation and investment in developing new and improved cardiac devices to address the growing patient population and enhance treatment outcomes. For instance, in May 2024, according to the Singapore Heart Foundation (SHF), a Singapore-based non-profit organization, ischemic heart disease resulted in 5,302 deaths, showing a slight increase from 5,290 deaths in 2022. Therefore, the rising incidence of heart disease drives the growth of the implantable cardiac devices industry.

Key Players In The Global Implantable Cardiac Devices Market

Major companies operating in the implantable cardiac devices market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Biotronik SE & Co. KG, LivaNova plc, Lepu Medical Technology, MicroPort Scientific Corporation, LifeTech Scientific Corporation, EBR Systems Inc., CVRx Inc., Medico S.p.A., Osypka Medical GmbH, Sorin Group Italia (LivaNova legacy), Shree Pacetronix Ltd., Inpace Medikal, CCC Medical Devices, Imricor Medical Systems Inc., BlueWind Medical Ltd., Vectorious Medical Technologies, Medico Electrodes International Ltd.

Global Implantable Cardiac Devices Market Trends and Insights

Major companies operating in the implantable cardiac devices market focus on enhancing compatibility with diagnostic tools such as AutoMRI to extend device lifespan and improve patient safety. The AutoMRI function in implantable cardiac defibrillators automatically adjusts the device settings to ensure safe operation during MRI scans, enhancing patient care while allowing access to advanced imaging technology. For instance, in October 2023, MicroPort CRM, a France-based medical device company, launched the ULYS implantable cardioverter defibrillator (ICD) and INVICTA defibrillation leads in Japan, featuring advanced technology with low current consumption for extended device lifespan and MRI compatibility. The ULYS ICD incorporates the PARAD+ arrhythmia discrimination algorithm and AutoMRI functionality, while the INVICTA lead delivers precise pacing and defibrillation therapy, demonstrating a 100% implantation success rate and 97.4% complication-free rate in clinical trials.

What Are Latest Mergers And Acquisitions In The Implantable Cardiac Devices Market?

In November 2023, Johnson & Johnson MedTech, a US-based medical-technology company, acquired Laminar Inc. for $400 million. This acquisition strengthens Johnson & Johnson MedTech’s position in the structural-heart and left-atrial-appendage management market by adding Laminar’s investigational LAAX left-atrial-appendage elimination technology to its portfolio. It further enhances the company’s capabilities in stroke-risk reduction for atrial-fibrillation patients through the addition of an innovative implantable device solution. Laminar Inc. is a US-based manufacturer of implantable cardiac devices.

Regional Outlook

North America was the largest region in the implantable cardiac devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Implantable Cardiac Devices Market?

The implantable cardiac devices market consists of sales of products including cardiac resynchronization therapy (CRT) devices, ventricular assist devices (VADs), and implantable heart monitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.